My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crucigrama Sopa de Letras Hoja de Trabajo
Calificar este Puzzle:
Log in or sign up to rate this puzzle.

The Cynical Scribe's Guide to the Top Twenty Suppliers of NGS Labs

Looking for actionable market intelligence on the US and Europe? 
Contact [email protected] for a zoom tour of our research.
Horizontales
We're #2. Our big sequencer gives small hospitals fast answers.
We're #4, fearsome in targeted sequencing libraries
We're #14. Agilent's lawyers were fierce, but we managed to parry them. We make synthetic DNA and NGS libraries
We're #17. Mostly robotics, but we bought Nugen in 2018, so we sell libraries too.
We're #18. Wuxi was only hard to say, so we changed are name to something harder to say.
We're #16. We sell libraries and robotics. We bought Horizon Discovery with our Covid windfall.
We're #12. We're Beckman's sister company. Danaher bought us in 2018.
We're #9 overall, #5 in libraries, and the #1 private company in the NGS business.
We're #15, and a small part of Merck Darmstadt since 2010.
We're #13. We're the incumbent power of digital PCR.
Verticales
We're #8. Illumina tried to buy us in 2018. We're doing a lot of things well, but our share price went from $29 to $5 over the last year. Predators are stalking us again.
We're #10 overall, and #1 in liquid handling robotics.
We're #20. We used to be called Fluidigm. Our old name was better.
We're #3, and the apex predator of single-cell markets
We're #11, but Illumina's lawyers have kept us out of the US so far. That changes at the end of this summer.
We're #6. We make the only sequencers you can put in your pocket.
We're 19 - the French bioinformatics team
We're #1. We created the ecosystem, but our patents expire soon. No rest for the weary.
We're #5, mostly libraries and bioinformatics, sample processing robotics and digital PCR too
We're #7. We offered $44.50/share for Illumina ten years ago. That was the wrong time to be stingy.